vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
SOLESENCE, INC. is the larger business by last-quarter revenue ($12.5M vs $9.5M, roughly 1.3× Cellectis S.A.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -265.9%, a 267.2% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs -0.7%).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
CLLS vs SLSN — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $12.5M |
| Net Profit | $-25.3M | $163.0K |
| Gross Margin | — | 27.5% |
| Operating Margin | -181.1% | 1.5% |
| Net Margin | -265.9% | 1.3% |
| Revenue YoY | 375.0% | -0.7% |
| Net Profit YoY | -51.9% | 129.2% |
| EPS (diluted) | $-0.28 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.5M | ||
| Q3 25 | — | $14.6M | ||
| Q2 25 | — | $20.4M | ||
| Q1 25 | — | $14.6M | ||
| Q4 24 | — | $12.6M | ||
| Q3 24 | — | $16.9M | ||
| Q2 24 | $9.5M | $13.0M | ||
| Q1 24 | — | $9.9M |
| Q4 25 | — | $163.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $2.7M | ||
| Q1 25 | — | $80.0K | ||
| Q4 24 | — | $-559.0K | ||
| Q3 24 | — | $3.0M | ||
| Q2 24 | $-25.3M | $856.0K | ||
| Q1 24 | — | $893.0K |
| Q4 25 | — | 27.5% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | 22.0% | ||
| Q3 24 | — | 36.2% | ||
| Q2 24 | — | 28.7% | ||
| Q1 24 | — | 36.3% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | — | -5.4% | ||
| Q2 25 | — | 9.4% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | -1.8% | ||
| Q3 24 | — | 19.0% | ||
| Q2 24 | -181.1% | 8.0% | ||
| Q1 24 | — | 11.3% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | -7.7% | ||
| Q2 25 | — | 13.1% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | — | 18.1% | ||
| Q2 24 | -265.9% | 6.6% | ||
| Q1 24 | — | 9.0% |
| Q4 25 | — | $0.00 | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | — | $0.04 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | — | $0.04 | ||
| Q2 24 | $-0.28 | $0.01 | ||
| Q1 24 | — | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $148.6M | $17.6M |
| Total Assets | $407.1M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3M | ||
| Q3 25 | — | $429.0K | ||
| Q2 25 | — | $4.1M | ||
| Q1 25 | — | $1.8M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $2.9M | ||
| Q2 24 | $149.0M | $2.4M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $17.2M | ||
| Q2 25 | — | $18.2M | ||
| Q1 25 | — | $15.2M | ||
| Q4 24 | — | $14.9M | ||
| Q3 24 | — | $15.2M | ||
| Q2 24 | $148.6M | $11.9M | ||
| Q1 24 | — | $5.0M |
| Q4 25 | — | $50.1M | ||
| Q3 25 | — | $54.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $57.0M | ||
| Q4 24 | — | $50.0M | ||
| Q3 24 | — | $48.0M | ||
| Q2 24 | $407.1M | $40.8M | ||
| Q1 24 | — | $38.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $1.8M |
| Free Cash FlowOCF − Capex | $27.6M | — |
| FCF MarginFCF / Revenue | 290.5% | — |
| Capex IntensityCapex / Revenue | 13.2% | — |
| Cash ConversionOCF / Net Profit | — | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $-2.5M | ||
| Q2 25 | — | $-654.0K | ||
| Q1 25 | — | $-7.2M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | — | $4.2M | ||
| Q2 24 | $28.9M | $-565.0K | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-404.0K | ||
| Q3 24 | — | $2.8M | ||
| Q2 24 | $27.6M | $-1.0M | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3.2% | ||
| Q3 24 | — | 16.6% | ||
| Q2 24 | 290.5% | -8.0% | ||
| Q1 24 | — | -39.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 20.6% | ||
| Q3 24 | — | 8.3% | ||
| Q2 24 | 13.2% | 3.7% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.25× | ||
| Q1 25 | — | -90.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | — | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
